CA Patent

CA2889238A1 — Method for reducing triglycerides

Assigned to Deakin University · Expires 2014-05-01 · 12y expired

What this patent protects

The present disclosure relates to docosapentaneoic acid (DPA) of the omega-3 type (DPA 22:5n-3) or derivative thereof and its use in reducing hypertriglyceridemia in a subject in need thereof. In particular, the disclosure relates to the ability of n-3 DPA to significantly decrea…

USPTO Abstract

The present disclosure relates to docosapentaneoic acid (DPA) of the omega-3 type (DPA 22:5n-3) or derivative thereof and its use in reducing hypertriglyceridemia in a subject in need thereof. In particular, the disclosure relates to the ability of n-3 DPA to significantly decrease the incorporation of fatty acids in chylomicrons in the post-prandial setting.

Drugs covered by this patent

Patent Metadata

Patent number
CA2889238A1
Jurisdiction
CA
Classification
—
Expires
2014-05-01
Drug substance claim
No
Drug product claim
No
Assignee
Deakin University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.